CSL Limited (OTCMKTS:CSLLY) Short Interest Update

CSL Limited (OTCMKTS:CSLLY) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 1,600 shares, a decline of 90.9% from the October 31st total of 17,500 shares. Based on an average daily volume of 89,900 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Separately, Macquarie upgraded shares of CSL to a “strong-buy” rating in a research note on Tuesday, August 13th.

CSL Stock Up 1.0 %

CSL stock traded up $0.89 during mid-day trading on Wednesday, reaching $91.19. 34,189 shares of the company were exchanged, compared to its average volume of 35,444. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58. The firm’s 50-day simple moving average is $96.31 and its two-hundred day simple moving average is $98.21. CSL has a twelve month low of $82.55 and a twelve month high of $109.00.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.